Virtus Lifesci Biotech Products Etf Newsroom

BioCryst Announces FDA Acceptance Of Its New Drug Application For Oral, Once Daily ORLADEYO In Hereditary Angioedema Patents Aged 2 To 11 Years

BenzingaMay 14 07:02 ET

Earnings Scheduled For May 14, 2025

BenzingaMay 14 04:32 ET

BEIGENE's Q1 loss narrowed to 94.503 million yuan, with Baiyueze and Baizean sales revenue increasing.

In the first quarter of 2025, BEIGENE achieved revenue of 8.048 billion yuan, a year-on-year increase of 50.2%; the net income attributable to the parent was a loss of 94.503 million yuan, compared to a loss of 1.908 billion yuan in the same period last year; In recent years, with policy support, China's Innovative Drugs Industry has entered a period of rapid development. In 2024, the industry will usher in a new round of policy dividends, and the research and development results of domestic Innovative Drugs will experience explosive growth.

cls.cnMay 13 21:40 ET

Earnings Preview: BeiGene

BenzingaMay 13 15:03 ET

Crude Oil Gains 3%; US Inflation Eases In April

BenzingaMay 13 13:11 ET

12 Health Care Stocks Moving In Tuesday's Intraday Session

BenzingaMay 13 13:06 ET

Biggest Stock Movers Tuesday: COIN, FSLR, UNH, and More

Seeking AlphaMay 13 09:57 ET

BridgeBio Pharma Has Dosed The First Asymptomatic Participant With A Known Pathogenic Transthyretin Variant, Which May Lead To Transthyretin Amyloid Disease In ACT-EARLY Study With Acoramidis

BenzingaMay 13 07:38 ET

Ascendis Pharma Announces New Data From Week 214 Of Its Phase 2 Path Forward Trial Showing That Long-Term Treatment With TransCon PTH Continued To Provide A Durable Response In Adults With Hypoparathyroidism

BenzingaMay 12 16:51 ET

Ascendis Pharma Analyst Ratings

BenzingaMay 12 11:30 ET · Ratings

BridgeBio To Present ATTRibute-CM Study Findings At Heart Failure 2025 Congress

BenzingaMay 12 07:32 ET

Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'

BenzingaMay 11 22:19 ET

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years

BenzingaMay 9 10:30 ET

RBC Capital Maintains Outperform on BeiGene, Lowers Price Target to $311

BenzingaMay 8 13:06 ET · Ratings

BeiGene Analyst Ratings

BenzingaMay 8 10:35 ET · Ratings

BeiGene Targets $4.9B-$5.3B Revenue for 2025 With Strong BRUKINSA and Pipeline Growth

Seeking AlphaMay 7 14:05 ET

12 Health Care Stocks Moving In Wednesday's Intraday Session

BenzingaMay 7 13:06 ET

Halozyme Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Guidance. Also, Wells Fargo Maintained an Equal-Weight Rating on the Stock and Raised Its Price Target From $60 to...

BenzingaMay 7 10:46 ET

Halozyme Therapeutics Analyst Ratings

BenzingaMay 7 09:57 ET · Ratings

BeiGene Shares Are Trading Lower After the Company Reported Mixed Q1 Financial Results.

BenzingaMay 7 07:28 ET